Bayer announced on Friday plans to invest 2.2 billion U.S. dollars in a new pharmaceutical manufacturing site in New Albany, Ohio. The project builds on more than seven billion dollars in U.S. pharma research, development and manufacturing spend over the past five years and is a central element of Bayer's long-term growth strategy in its largest pharmaceuticals market. Bayer expects to create around 600 high-value jobs in the New Albany International Business Park and roughly 1,500 construction jobs during the facility's construction. The flexible, modular campus will combine drug substance and drug product manufacturing and initially support Bayer's growing portfolio in oncology, cardiovascular and renal care, with the first drug substance module expected to become operational in 2031 and a second drug product module planned for 2034. The new site will complement Bayer's U.S. pharmaceuticals headquarters in Whippany, New Jersey, and its other sites in Pittsburgh, Berkeley, Cambridge, Research Triangle Park and San Diego.
Bayer AG NABayer plans a $2.2B investment in a new Ohio pharma manufacturing site, a central element of its long-term growth strategy.
